Recurrent inactivating RASA2 mutations in melanoma

Rand Arafeh, Nouar Qutob, Rafi Emmanuel, Alona Keren-Paz, Jason Madore, Abdel Elkahloun, James S. Wilmott, Jared J. Gartner, Antonella Di Pizio, Sabina Winograd-Katz, Sivasish Sindiri, Ron Rotkopf, Ken Dutton-Regester, Peter A. Johansson, Antonia L. Pritchard, Nicola Waddell, Victoria K. Hill, Jimmy C. Lin, Yael Hevroni, Steven A. RosenbergJaved Khan, Shifra Ben-Dor, Masha Y. Niv, Igor Ulitsky, Graham J. Mann, Richard A. Scolyer, Nicholas K. Hayward, Yardena Samuels

Research output: Contribution to journalArticlepeer-review

78 Citations (Scopus)


Analysis of 501 melanoma exomes identified RASA2, encoding a RasGAP, as a tumor-suppressor gene mutated in 5% of melanomas. Recurrent loss-of-function mutations in RASA2 were found to increase RAS activation, melanoma cell growth and migration. RASA2 expression was lost in ≥30% of human melanomas and was associated with reduced patient survival. These findings identify RASA2 inactivation as a melanoma driver and highlight the importance of RasGAPs in cancer.
Original languageEnglish
Pages (from-to)1408-1410
Number of pages3
JournalNature Genetics
Issue number12
Early online date26 Oct 2015
Publication statusPublished - Dec 2015


  • 3ref2021


Dive into the research topics of 'Recurrent inactivating RASA2 mutations in melanoma'. Together they form a unique fingerprint.

Cite this